SAREPTA THERAPEUTICS, INC. (SRPT) FY2026 YTD Q2 Statement of Cash Flows

Statement of Cash Flows

2026-01-01 to 2026-06-30

Swipe to see the full flow
SAREPTA THERAPEUTICS, INC. cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Orange marks positive customer-advance and deferred-revenue changes that add to operating cash in the reconciliation. These are net changes, not gross customer receipts. Negative changes are neutral reconciliation adjustments; they do not by themselves identify cash payments. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Proceeds from borrowings under the Revolving Credit Facility → financing reconciliation: $425,000,000.00Proceeds from exercise of stock options and purchase of stock under the Employee Stock Purchase Program → financing reconciliation: $241,000.00financing reconciliation → Net cash from financing activities: $241,000.00financing reconciliation → Repayments of borrowings under the Revolving Credit Facility: $425,000,000.00Maturity and sales of available-for-sale securities → investing reconciliation: $126,919,000.00Net cash used in investing activities → investing reconciliation: $227,762,000.00investing reconciliation → Purchase of investments: $351,045,000.00investing reconciliation → Purchase of property and equipment: $2,636,000.00investing reconciliation → Purchase of intangible assets: $1,000,000.00Net cash used in operating activities → operating reconciliation: $5,613,000.00Net income (loss) → operating reconciliation: $326,069,000.00Decrease in manufacturing-related deposits and prepaids → operating reconciliation: $69,279,000.00Increase in other assets → operating reconciliation: $67,840,000.00Stock-based compensation → operating reconciliation: $53,871,000.00Decrease (increase) in accounts receivable → operating reconciliation: $21,409,000.00Depreciation and amortization → operating reconciliation: $21,003,000.00Non-cash interest expense → operating reconciliation: $19,006,000.00Non-cash inventory write-downs for obsolescence → operating reconciliation: $11,599,000.00Reduction in the carrying amounts of the right of use assets → operating reconciliation: $6,322,000.00(Decrease) increase in lease liabilities and other liabilities → operating reconciliation: $2,640,000.00Loss on strategic investments → operating reconciliation: $2,160,000.00operating reconciliation → Decrease in deferred revenue: $307,043,000.00operating reconciliation → Decrease in accounts payable: $229,859,000.00operating reconciliation → (Decrease) increase in accrued expenses: $37,331,000.00operating reconciliation → Increase in inventory: $29,845,000.00operating reconciliation → Accretion of investment discount, net: $1,435,000.00operating reconciliation → Other: $1,298,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $814,407,000.00Net cash from financing activities → Cash sources and uses: $241,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $581,273,000.00Cash sources and uses → Net cash used in investing activities: $227,762,000.00Cash sources and uses → Net cash used in operating activities: $5,613,000.00Net income (loss): $326,069,000.00Net income (loss)+$326.07 MLoss on strategic investments: $2,160,000.00Investment gain & loss+$2.16 MStock-based compensation: $53,871,000.00Stock-based compensation+$53.87 MDepreciation and amortization: $21,003,000.00Depreciation & amortization+$21.00 MNon-cash inventory write-downs for obsolescence: $11,599,000.00Inventory write-downs+$11.60 MNon-cash interest expense: $19,006,000.00Non-cash interest expense+$19.01 MReduction in the carrying amounts of the right of use assets: $6,322,000.00Right-of-use assets+$6.32 MAccretion of investment discount, net: -$1,435,000.00Discount accretion, net−$1.44 MOther: -$1,298,000.00Other non-cash items−$1.30 MDecrease (increase) in accounts receivable: $21,409,000.00Accounts receivable+$21.41 MDecrease in manufacturing-related deposits and prepaids: $69,279,000.00Manufacturing deposits & prepaids+$69.28 MIncrease in inventory: -$29,845,000.00Inventories−$29.85 MIncrease in other assets: $67,840,000.00Other operating assets+$67.84 MDecrease in deferred revenue: -$307,043,000.00Unearned revenue−$307.04 MDecrease in accounts payable: -$229,859,000.00Accounts payable−$229.86 M(Decrease) increase in accrued expenses: -$37,331,000.00Accrued liabilities−$37.33 M(Decrease) increase in lease liabilities and other liabilities: $2,640,000.00Accrued & other liabilities+$2.64 MNet cash used in operating activities: -$5,613,000.00. Cash required to fund net payments.Operating cash−$5.61 Moperating reconciliation: $606,811,000.00Proceeds from exercise of stock options and purchase of stock under the Employee Stock Purchase Program: $241,000.00Stock option exercises+$241.00 KProceeds from borrowings under the Revolving Credit Facility: $425,000,000.00Credit line borrowings+$425.00 MRepurchases of common stock: $0.00Repayments of borrowings under the Revolving Credit Facility: -$425,000,000.00Credit line repayments−$425.00 MPayments related to obtaining Revolving Credit Facility: $0.00Net cash from financing activities: $241,000.00Financing cash+$241.00 Kfinancing reconciliation: $425,241,000.00Purchase of investments: -$351,045,000.00Investment purchases−$351.05 MPurchase of property and equipment: -$2,636,000.00PP&E purchases−$2.64 MMaturity and sales of available-for-sale securities: $126,919,000.00AFS securities proceeds+$126.92 MPurchase of intangible assets: -$1,000,000.00Intangible asset purchases−$1.00 MAcquisition of strategic investments: $0.00Net cash used in investing activities: -$227,762,000.00. Cash required to fund net payments.Investing cash−$227.76 Minvesting reconciliation: $354,681,000.00Cash sources and uses: $814,648,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $814,407,000.00Beginning cash$814.41 MEnding cash: Cash, cash equivalents, and restricted cash: $581,273,000.00Ending cash$581.27 MCASH RECONCILIATIONFinancingflowsInvestingflowsOperatingflowsFree cash flow−$8.25 MOperating cash − cash spent on PP&ECash flow / Net income−0.02×Operating cash flow ÷ net incomeNet cash change−$233.13 MEnding cash − beginning cash
Chart details

SAREPTA THERAPEUTICS, INC. cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026

Cash flows for Jan 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2025. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Dec 31, 2025
814,407,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
negative 5,613,000 US dollars. Net cash used.
Net income (loss)
326,069,000 US dollars
Loss on strategic investments
2,160,000 US dollars
Stock-based compensation
53,871,000 US dollars
Depreciation and amortization
21,003,000 US dollars
Non-cash inventory write-downs for obsolescence
11,599,000 US dollars
Non-cash interest expense
19,006,000 US dollars
Reduction in the carrying amounts of the right of use assets
6,322,000 US dollars
Accretion of investment discount, net
negative 1,435,000 US dollars
Other
negative 1,298,000 US dollars
Decrease (increase) in accounts receivable
21,409,000 US dollars
Decrease in manufacturing-related deposits and prepaids
69,279,000 US dollars
Increase in inventory
negative 29,845,000 US dollars
Increase in other assets
67,840,000 US dollars
Decrease in deferred revenue
negative 307,043,000 US dollars
Decrease in accounts payable
negative 229,859,000 US dollars
(Decrease) increase in accrued expenses
negative 37,331,000 US dollars
(Decrease) increase in lease liabilities and other liabilities
2,640,000 US dollars
Investing activities
negative 227,762,000 US dollars. Net cash used.
Purchase of investments
negative 351,045,000 US dollars
Purchase of property and equipment
negative 2,636,000 US dollars
Maturity and sales of available-for-sale securities
126,919,000 US dollars
Purchase of intangible assets
negative 1,000,000 US dollars
Acquisition of strategic investments
0 US dollars
Financing activities
241,000 US dollars. Net cash provided.
Proceeds from exercise of stock options and purchase of stock under the Employee Stock Purchase Program
241,000 US dollars
Proceeds from borrowings under the Revolving Credit Facility
425,000,000 US dollars
Repurchases of common stock
0 US dollars
Repayments of borrowings under the Revolving Credit Facility
negative 425,000,000 US dollars
Payments related to obtaining Revolving Credit Facility
0 US dollars
Operating adjustment reconciliation
606,811,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
425,241,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
354,681,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
0 US dollars
Ending cash on Jun 30, 2026
581,273,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
814,648,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
negative 233,134,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
−0.02×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
Operating cash flow
negative 5,613,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
2,636,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
negative 8,249,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net income or operating cash is negative. The full signed reconciliation is retained: losses remain deductions, and any negative operating-cash total enters the junction from the cash pool. No positive direct-income connection is implied.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: negative 5,613,000 US dollars minus 2,636,000 US dollars equals negative 8,249,000 US dollars.
SAREPTA THERAPEUTICS, INC. (SRPT) FY2026 YTD Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!